VASOXYL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASOXYL is an injectable small-molecule vasopressor approved in 1949 by GSK. The drug's mechanism of action and specific indications are not publicly detailed in available records. It is used as an intravenous injection for hemodynamic support.
LOE Approaching
With LOE approaching, the brand team is likely consolidating roles and shifting focus to legacy management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VASOXYL offers limited career growth potential as a legacy injectable approaching loss of exclusivity with minimal linked job openings. Roles focus on institutional sales, cost management, and relationship preservation rather than innovation or market expansion.
Brand Manager (Legacy)Field Sales Representative
Worked on VASOXYL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.